On August 17, 2023, Camac Partners, LLC announced that it has filed a revised preliminary proxy statement with Securities and Exchange Commission, requesting the shareholders of Forte Biosciences to vote for the election of its 2 nominees, Michael G. Hacke and Chris McIntyre, and vote against for the 2 Company nominees, Lawrence Eichenfield and Paul A. Wagner. Additionally, Camac Partners, LLC urged shareholders to vote against Company proposal to approve, on an advisory basis, the compensation of the Company?s named executive officers at its 2023 annual general meeting of shareholders.
Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
0.651 USD | +1.72% | -10.65% | -20.90% |
05-13 | Tocagen Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024 | CI |
03-18 | Forte Biosciences, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023 | CI |
Quarterly revenue - Rate of surprise
1st Jan change | Capi. | |
---|---|---|
-20.90% | 23.29M | |
+7.81% | 113B | |
+10.90% | 106B | |
+0.41% | 22.27B | |
-11.99% | 22.22B | |
-5.99% | 19.43B | |
-37.36% | 17.87B | |
-5.48% | 17.24B | |
+6.70% | 14.29B | |
+35.78% | 12.52B |
- Stock Market
- Equities
- FBRX Stock
- News Forte Biosciences, Inc.
- Camac Partners, LLC Files a Revised Preliminary Proxy Statement with Securities and Exchange Commission